UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG

Following FDA Approval

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

The Belgian firm’s Rystiggo may be the second drug of its class to win approval, but a broad label encompassing two major patient groups in generalized myasthenia gravis could set it apart as work starts for a launch later this year.  

blue light bulb in middle of row of white light bulbs against yellow background
Rystiggo Is The First Targeted Option For Patients With MuSK • Source: Shutterstock

Key Takeaways:

  • UCB is gearing up for a US product launch in Q3 with filings under review in the EU and Japan.

UCB S.A.’s Rystiggo has won a US Food and Drug Administration green light to treat two major subtypes of generalized myasthenia gravis (gMG), making it the second human neonatal Fc receptor (FcRn) inhibitor to reach the market just after rival argenx N.V.’s Vyvgart.

On 27 June, the FDA approved Rystiggo (rozanolixizumab) for gMG patients with autoantibodies to the anti-acetylcholine receptor (AChR) or muscle-specific...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.